NanoViricides Inc. (NNVC)

[JG36]

That's a mighty small number of patients for a phase III trial. Except for exotic diseases where the total number of patients available for trials is tiny, typically phase III trials have a minimum of 1000 patients, with 2000 or more (sometimes a lot more) being common.

If there are only 500 patients in the phase III trial we'll just have to hope that the results are so spectacular that even the FDA agrees they are statistically significant. And the FDA loves to find reasons not to approve drugs.